

Announcement Summary

Entity name

MGC PHARMACEUTICALS LTD

Announcement Type

New announcement

Date of this announcement

Friday July 14, 2023

The +securities to be quoted are: ☑ Other

Total number of +securities to be quoted

ASX +security	/	Number of +securities to	Issue date
code	Security description	be quoted	
MXC	ORDINARY FULLY PAID	541,666,667	14/07/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MGC PHARMACEUTICALS LTD

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type ACN

Registration number 116800269

1.3 ASX issuer code MXC

1.4 The announcement is

C New announcement

1.5 Date of this announcement

14/7/2023



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

C Other

- 2.2 The +securities to be quoted are:
- C Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? $\ensuremath{\mathfrak{C}}$ No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Refer to https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02686829-6A1158435?access_token=83ff96335c2d45a094df02a206a39ff4



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an

Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description MXC : ORDINARY FULLY PAID

Issue date

14/7/2023

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? If Yes

Issue details

Number of +securities to be quoted				
541,666,667				
Are the +securities being issued for a cash consideration? ☑ Yes				
In what currency is the cash consideration being paid?	What is the issue price per +security?			
GBP - Pound Sterling	GBP 0.00120000			
Any other information the entity wishes to provide about the +securities to be quoted				

Refer to https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02686725-6A1158398?access_token=83ff96335c2d45a094df02a206a39ff4

The purpose(s) for which the entity is issuing the securities

To raise additional working capital



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
MXC : ORDINARY FULLY PAID	3,892,359,617

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MXCAAG : OPTION EXPIRING 12-APR-2024 EX \$0.012	166,035,793
MXCAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	110,300,000
MXCAG : PERFORMANCE RIGHTS	12,500,000
MXCAAA : CONVERTIBLE NOTES	7,306,432
MXCAAD : CLASS C PERFORMANCE RIGHTS	5,400,000
MXCAAE : CLASS D PERFORMANCE RIGHTS	250,000
MXCAAF : CLASS E PERFORMANCE RIGHTS	250,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? S No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

🕑 Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

29/6/2023